Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the same period. This investor optimism stems from massive demand for the ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Eli Lilly & Co.’s shares dropped in premarket trading after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound, making rival Wegovy more widely available.

Michael Nagle / Bloomberg via Getty Images Shares of Eli Lilly (LLY ... of the $2.33 billion consensus. Revenue Outlook Affirmed, Profit Forecasts Cut Lilly affirmed its full-year revenue guidance ...

From a fundamental standpoint, Eli Lilly presently has a market capitalization of $789 billion. Over the trailing twelve months, the company has generated $45 billion in revenue, resulting in an ...

Eli Lilly (NYSE:LLY) shares trended lower in the premarket on Thursday after the Indiana-based drugmaker lowered its full-year non-GAAP earnings outlook to a level below consensus, despite surging ...

The head of drugmaker Eli Lilly, which sells the popular ... tariffs currently in effect do not materially change Lilly’s 2025 financial outlook,” he said. “However, the expansion of tariffs ...

Novo Nordisk and Eli Lilly , the leaders in the highly lucrative weight-loss drugs market, are competing against each other and several other drugmakers for next-generation treatments for obesity.

The company missed its earnings per share (EPS) forecast, reporting $3.34 against an expected $3.46. The market reacted negatively, with Eli Lilly’s stock dropping 8.56% in pre-market trading.